Digestive System Neoplasms (Cancer of the Digestive System)

Tumors or cancer of the DIGESTIVE SYSTEM.

Also Known As:

Cancer of the Digestive System; Neoplasms, Digestive System; Cancer, Digestive System; Cancers, Digestive System; Digestive System Cancers; Digestive System Neoplasm; Neoplasm, Digestive System; Cancer of Digestive System; Digestive System Cancer

Networked: 236 relevant articles (8 outcomes, 38 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Pancreatic Neoplasms (Pancreatic Cancer)
3.	Colonic Neoplasms (Colon Cancer)
4.	Stomach Neoplasms (Stomach Cancer)
5.	Colorectal Neoplasms (Colorectal Cancer)

Experts

1.	Willett, Walter C: 3 articles (01/2022 - 04/2006)
2.	Giovannucci, Edward: 3 articles (12/2007 - 04/2006)
3.	Mirzaei, Hamed: 2 articles (08/2022 - 01/2021)
4.	Cao, Bangwei: 2 articles (01/2022 - 01/2021)
5.	Ma, Xiao: 2 articles (01/2022 - 01/2021)
6.	Ma, Yan: 2 articles (01/2022 - 01/2021)
7.	Ma, Zhongjun: 2 articles (01/2022 - 01/2021)
8.	Wang, Jing: 2 articles (01/2022 - 01/2021)
9.	Wang, Jingting: 2 articles (01/2022 - 01/2021)
10.	Liu, Rongqiang: 2 articles (04/2021 - 01/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Digestive System Neoplasms:

1.	Biomarkers (Surrogate Marker)IBA 08/01/2016 - "This study was designed to investigate the potential value of MALAT1 as a prognostic biomarker in digestive system cancers. " 05/17/2016 - "This study was designed to investigate the potential value of MALAT1 as a prognostic biomarker in digestive system cancers. " 11/06/2023 - "Therefore, P2X7R may serve as a biomarker or therapeutic target for digestive system cancers. " 06/01/2022 - "The serum-derived EV-RNAs of ANLN, ITGA6, KRT18, and MMP9 could be served as novel, non-invasive biomarkers for digestive system cancers." 01/01/2021 - "We discuss the potential role of miR-145 as a valuable biomarker for digestive system cancers and how miR-145 regulates these digestive system cancers via different targets to explore the potential strategy of targeting miR-145."
2.	MicroRNAs (MicroRNA)IBA 02/03/2021 - "Our study identified significant miRNA signatures with improved prognosis accuracy in digestive system cancers. " 02/03/2021 - "A Cluster-Based Approach for Identifying Prognostic microRNA Signatures in Digestive System Cancers." 12/01/2020 - "MicroRNA-149: A review of its role in digestive system cancers." 10/23/2018 - "In the current review, we will discuss recent findings about inhibitors of HGF/c-MET signaling in treating digestive system cancers, and how miRNAs regulate digestive system cancers via mediating HGF/c-MET pathway." 10/23/2018 - "Recent reports show that several microRNAs participate in inhibiting HGF/c-MET signaling networks through antagonizing c-MET or HGF in digestive system cancers, and the miRNAs-HGF/c-MET axis plays crucial and novel roles for cancer treatment. "
3.	Chimeric Antigen ReceptorsIBA 05/01/2022 - "The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis." 05/01/2021 - "Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers." 05/01/2022 - "As a successful treatment for hematological malignancy, chimeric antigen receptor T cells (CAR-T cells) have been expanded to solid tumors to demonstrate their safety and efficacy, especially for digestive system cancer (DSC). " 12/01/2021 - "Chimeric antigen receptor (CAR) T-cell therapy has had limited efficacy against solid tumors, but a CAR T-cell therapy targeting isoform 2 of the tight junction membrane protein claudin 18, preferentially expressed on stomach mucosal cells, showed acceptable safety and promising efficacy against advanced digestive system cancers in a phase I trial."
4.	Cytochrome P-450 CYP2C19IBA 01/01/2013 - "Overall, significantly elevated digestive system cancer risk was associated CYP2C19 PM with OR of 1.66 (95%CI: 1.31-2.10, P<10(-5)) when all studies were pooled into the meta-analysis. " 01/01/2013 - "In the past decade, the relationship between CYP2C19 polymorphism and digestive system cancer has been reported in various ethnic groups; however, these studies have yielded contradictory results. " 01/01/2013 - "In summary, our meta-analysis suggested that the PM phenotype caused by the variation on CYP2C19 gene is associated with increased risk of digestive system cancer, especially in East Asians." 01/01/2013 - "Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects." 01/01/2013 - "CYP2C19 belongs to the cytochrome P450 superfamily of enzymes involved in activating and detoxifying many carcinogens and endogenous compounds, which has attracted considerable attention as a candidate gene for digestive system cancer. "
5.	ClaudinsIBA 01/01/2023 - "Claudin 18.2 (CLDN18.2) is a reliable target for lesion detection and could have clinical implications for epithelial tumors, especially digestive system neoplasms. " 12/01/2021 - "Chimeric antigen receptor (CAR) T-cell therapy has had limited efficacy against solid tumors, but a CAR T-cell therapy targeting isoform 2 of the tight junction membrane protein claudin 18, preferentially expressed on stomach mucosal cells, showed acceptable safety and promising efficacy against advanced digestive system cancers in a phase I trial."
6.	Metformin (Glucophage)FDA LinkGeneric 10/24/2022 - "Subgroup analyses demonstrated that metformin treatment was associated with a marginally significant improvement in PFS in reproductive system cancers (HR 0.86, 95% CI 0.74-1.00) and a significantly worse PFS in digestive system cancers (HR 1.45, 95% CI 1.03-2.04). " 10/24/2022 - "However, metformin implied beneficial effects in the PFS of the patients with reproductive system cancers but was related to a worse PFS in digestive system cancers. " 01/01/2016 - "In this review, we summarized the molecular mechanisms underlying anticancer effects of metformin, which included insulin- and AMPK-dependent effects, selectively targeting cancer stem cells, reversing multidrug resistance, inhibition of the tumor metastasis and described the antineoplastic effects of metformin combined with chemotherapeutic agents in digestive system cancers (colorectal, gastric, hepatic and pancreatic cancer), reproductive system cancers (ovarian and endometrial cancer), prostate cancer, breast cancer, lung cancer, etc. Moreover, the clinical trials regarding metformin in combination of chemotherapeutic drugs were presented and the clinical obstacle or limitation related to the potential role of metformin in cancer treatment was also discussed in this review."
7.	AntioxidantsIBA 08/08/2022 - "Molecular mechanisms and observational studies have found that diet-derived antioxidants are associated with digestive system cancers, whereas there is a lack of causal evidence from randomized clinical trials. " 08/08/2022 - "Investigating Causal Associations of Diet-Derived Circulating Antioxidants with the Risk of Digestive System Cancers: A Mendelian Randomization Study." 08/08/2022 - "Genetically determined antioxidants were not significantly associated with five digestive system cancers, after correcting for multiple tests. " 01/01/2022 - "Vitamin C is an antioxidant with a potential role in the prevention of digestive system cancers, but there is yet no consensus whether vitamin C has a causal role in these cancers. " 08/08/2022 - "Our findings suggest that higher levels of antioxidants are unlikely to be a causal protective factor for most digestive system cancers, except for the suggestive protective effects of ascorbate on colon cancer and of retinol on pancreatic cancer."
8.	Protein Isoforms (Isoforms)IBA 12/01/2021 - "Chimeric antigen receptor (CAR) T-cell therapy has had limited efficacy against solid tumors, but a CAR T-cell therapy targeting isoform 2 of the tight junction membrane protein claudin 18, preferentially expressed on stomach mucosal cells, showed acceptable safety and promising efficacy against advanced digestive system cancers in a phase I trial."
9.	Membrane Proteins (Integral Membrane Proteins)IBA 12/01/2021 - "Chimeric antigen receptor (CAR) T-cell therapy has had limited efficacy against solid tumors, but a CAR T-cell therapy targeting isoform 2 of the tight junction membrane protein claudin 18, preferentially expressed on stomach mucosal cells, showed acceptable safety and promising efficacy against advanced digestive system cancers in a phase I trial."
10.	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/01/2014 - "Published data regarding associations between the -765G>C polymorphism in cyclooxygenase-2 (COX-2) gene and digestive system cancer risk have been inconclusive. " 01/01/2014 - "The -765G>C polymorphism in the cyclooxygenase-2 gene and digestive system cancer: a meta-analysis." 01/01/2023 - "The FCTF model of the local medicinal food Laoxianghuang focuses on the efficacy of digestive system cancers and neurological diseases, with key targets ACE, PTGS2, CYP2C19 and corresponding active components citronellal, trans-nerolidol, linalool, geraniol, α-terpineol, cadinene and α-pinene. "

Therapies and Procedures

1.	Therapeutics 01/01/2022 - "All clinical trials of ICI-based therapies for digestive system cancers were investigated, including only randomized controlled trials that reported data on the overall incidence of treatment-related adverse events (trAEs) or immune-related adverse reactions (irAEs) or tables. " 01/01/2022 - "Natural cell based biomimetic cellular transformers for targeted therapy of digestive system cancer." 11/01/2019 - "ncRNAs associated with drug resistance and the therapy of digestive system neoplasms." 01/01/2017 - "In addition, PD-L1 may act as a new parameter for predicting poor prognosis and a promising target for anticancer therapy in digestive system cancers." 01/10/2003 - "[Complications of early-stage digestive system neoplasms treated with endoscopic therapy and the prognosis ]."
2.	Immunotherapy 12/01/2022 - "Therefore, it is crucially important to understand both the various different types of immunotherapy and the immune landscapes in digestive system neoplasms in order to reduce the side effects associated with these therapies. " 12/01/2022 - "Digestive system neoplasms pose a serious threat to human health, including esophageal cancer, gastric cancer and colorectal cancer, and immunotherapy is considered to be a promising new avenue for the treatment of digestive system neoplasms. " 01/01/2022 - "In view of the limited clinical benefits of immunotherapy in patients with digestive system cancers, as well as the side-effects and high treatment costs, development of biomarkers to predict the efficacy of immune therapy is a key imperative. " 01/01/2022 - "In this article, we review the available evidence of the value of microsatellite mismatch repair, tumor mutation burden, specific mutated genes or pathways, PD-L1 expression, immune-related adverse reactions, blood biomarkers, and patient-related biomarkers in predicting the efficacy of immunotherapy against digestive system cancers. "
3.	Phototherapy (Light Therapy) 04/01/1987 - "Clinical application and the efficacy of photoradiation therapy on digestive system neoplasms]."
4.	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/17/2008 - "The nightshade (Solanum nigrum Linn.) has been widely used in Chinese traditional medicine as a remedy for the treatment of digestive system cancer. "
5.	Drug Therapy (Chemotherapy) 04/01/2016 - "The elemental diet (ED) Elental® reportedly reduces adverse reactions to chemotherapy in digestive system cancer patients; however, the mechanism is unclear. " 05/01/2012 - "Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy." 01/01/1999 - "[Caring for cases of digestive system cancer treated by combined radiotherapy and chemotherapy]." 01/01/2023 - "The current treatment methods include surgical treatment, chemotherapy, radiotherapy and endoscopic treatment, and the precisely targeted therapy of digestive system cancers requires to be further studied. " 01/15/2015 - "Indeed, HIF-2α has been shown to regulate multiple aspects of digestive system cancers, including cell proliferation, angiogenesis and apoptosis, metabolism, metastasis and resistance to chemotherapy. "